Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32839
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPerret, Jennifer L-
dc.contributor.authorYip, Sui Wah Sean-
dc.contributor.authorIdrose, Nur Sabrina-
dc.contributor.authorHancock, Kerry-
dc.contributor.authorAbramson, Michael J-
dc.contributor.authorDharmage, Shyamali C-
dc.contributor.authorWalters, E Haydn-
dc.contributor.authorWaidyatillake, Nilakshi-
dc.date.accessioned2023-05-12T02:59:48Z-
dc.date.available2023-05-12T02:59:48Z-
dc.date.issued2023-04-
dc.identifier.citationBMJ Open Respiratory Research 2023; 10(1)en_US
dc.identifier.issn2052-4439-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32839-
dc.description.abstractDespite chronic obstructive pulmonary disease (COPD) being a major global cause of mortality and hospitalisation, it is often undiagnosed or inaccurately diagnosed in clinical settings. To systematically synthesise all peer-reviewed papers from primary healthcare settings that have reported data on: (1) undiagnosed COPD, that is, patients with respiratory symptoms and postbronchodilator airflow obstruction consistent with COPD, without a formal clinician's diagnosis of COPD either documented in health records or reported by patients and (2) 'overdiagnosed COPD', that is, clinician's diagnosis without postbronchodilator airflow obstruction. Studies investigating these diagnostic metrics in patients from primary healthcare clinics (according to predefined inclusion/exclusion criteria) were sourced from Medline and Embase and assessed for bias (Johanna Briggs Institute tools for prevalence studies and case series). Meta-analyses of studies of adequate sample size used random effect modelling stratified by risk factor categories. Of 26 eligible articles, 21 cross-sectional studies investigated 3959 cases of spirometry-defined COPD (with or without symptoms), and 5 peer-reviewed COPD case series investigated 7381 patients. The prevalence of spirometry-confirmed COPD without a diagnosis documented in their health records was 14%-26% in studies of symptomatic smokers (N=3). 1 in 4 patients taking inhaled therapies (25% (95% CI 22% to 28%), N=2) and 1 in 6 smokers irrespective of symptoms (16% (95% CI 14% to 18%), N=6) fulfilled diagnostic spirometry criteria but did not report receiving a COPD-related diagnosis. In an adequately powered series of COPD cases documented in primary healthcare records (N=4), only between 50% and 75% of subjects had any airflow obstruction on postbronchodilator spirometry performed by study researchers, therefore, COPD was clinically 'overdiagnosed' in 25%-50% of subjects. Although data were heterogeneous and of modest quality, undiagnosed COPD was common in primary healthcare, especially for symptomatic smokers and patients treated with inhaled therapies. In contrast, frequent COPD 'overdiagnosis' may represent treatment of asthma/reversible component or another medical diagnosis. CRD42022295832.en_US
dc.language.isoeng-
dc.subjectCOPD epidemiologyen_US
dc.subjectClinical epidemiologyen_US
dc.titleUndiagnosed and 'overdiagnosed' COPD using postbronchodilator spirometry in primary healthcare settings: a systematic review and meta-analysis.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMJ Open Respiratory Researchen_US
dc.identifier.affiliationAllergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationRespiratory and Sleep Medicineen_US
dc.identifier.affiliationInstitute for Breathing and Sleepen_US
dc.identifier.affiliationMelbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationChandlers Hill Surgery, Happy Valley, South Australia, Australia.en_US
dc.identifier.affiliationSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationSchool of Medicine, University of Tasmania, Hobart, Tasmania, Australia.en_US
dc.identifier.affiliationDepartment of Medical Education, The University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.doi10.1136/bmjresp-2022-001478en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-7034-0615en_US
dc.identifier.orcid0000-0002-9954-0538en_US
dc.identifier.pubmedid37130651-
dc.description.volume10-
dc.description.issue1-
dc.subject.meshtermssecondarySmoking/adverse effects-
dc.subject.meshtermssecondarySmoking/epidemiology-
dc.subject.meshtermssecondaryPulmonary Disease, Chronic Obstructive/diagnosis-
dc.subject.meshtermssecondaryPulmonary Disease, Chronic Obstructive/epidemiology-
dc.subject.meshtermssecondaryPulmonary Disease, Chronic Obstructive/drug therapy-
local.name.researcherPerret, Jennifer L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.languageiso639-1en-
crisitem.author.deptInstitute for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Sep 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.